May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Effect of Retinol Palmitate Eye Drops on Experimental Keratoconjunctival Epithelial Damage Induced by n-heptanol in Rabbit
Author Affiliations & Notes
  • A. Odaka
    Pharmaceutical Research Laboratories No.1 Pharmaceutical Products Division, Lion Corporation, Kanagawa, Japan
    Department of Ophthalmology, Juntendo University School of Medicine, Tokyo, Japan
  • H. Toshida
    Department of Ophthalmology, Juntendo University School of Medicine, Tokyo, Japan
  • D. Koike
    Pharmaceutical Research Laboratories No.1 Pharmaceutical Products Division, Lion Corporation, Kanagawa, Japan
  • A. Murakami
    Department of Ophthalmology, Juntendo University School of Medicine, Tokyo, Japan
  • Footnotes
    Commercial Relationships  A. Odaka, None; H. Toshida, None; D. Koike, None; A. Murakami, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 3393. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. Odaka, H. Toshida, D. Koike, A. Murakami; Effect of Retinol Palmitate Eye Drops on Experimental Keratoconjunctival Epithelial Damage Induced by n-heptanol in Rabbit. Invest. Ophthalmol. Vis. Sci. 2008;49(13):3393. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : The efficacy of vitamin A for keratoconjunctival disease has been reported, and improvement of keratosis of the keratoconjuntival epithelium and an increase of conjunctival goblet cells have been demonstrated. We investigated the effects of vitamin A (retinol palmitate (VApal)) eye drops in rabbit models of corneal and conjuntival epithelial damage after n-heptanol treatment.

Methods: : After keratoconjunctival injury by 20 µL of n-heptanol, VApal eye drops (500, 1,000 or 1,500 IU/mL) or vehicle were started six times a day for 11 days. Fluorescein and rose bengal staining and histological analysis (HE and PAS staining) were performed.

Results: : The fluorescein score was significantly reduced in the 1,000 IU/mL and 1,500 IU/mL VApal-treated eyes compared with the vehicle-treated eyes at 7 and 9 days after treatment (p<0.05). The rose bengal score was significantly reduced in the VApal-treated eyes compared with the vehicle-treated eyes at 7, 9, and 11 days after treatment with 500 IU/mL (p<0.05) of VApal, at 5, 7, and 9 days after treatment with 1,000 IU/mL (p<0.01) of VApal, and at 3, 5, and 7 days (p<0.01) and 9 and 11 days (p<0.05) after treatment with 1,500 IU/mL of VApal. Histological examination revealed that the keratoconjunctival epithelial defect was healed and the increased number of goblet cells was noted at 7 days after treatment with VApal (1,500 IU/mL) more than vehicle.

Conclusions: : VApal eye drops may be useful in treatment of keratoconjunctival injury, and the earlier improvement of the rose bengal score than that of the fluorescein socore suggests the possibility that tear mucin film was stabilized at an early stage by VApal.

Keywords: cornea: epithelium • cornea: surface mucins • cornea: tears/tear film/dry eye 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×